Investigating a new treatment for dementia with Lewy bodies
Official title: A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
Funded at Eip Pharma, INC. · NIH-11019686 · Data updated 2026-11-12
This study is looking at how well a new oral medication called neflamapimod can help improve thinking and movement problems in people with mild-to-moderate dementia with Lewy bodies, a condition that currently has no approved treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eip Pharma, INC. NIH-funded |
| Lab location | 1 site (Boston, UNITED STATES) |
| Project start | February 1, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $6,072,987 |
| NIH project number | 5R01AG080536-03 |
| Project ID | NIH-11019686 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with mild-to-moderate dementia with Lewy bodies.
✕Less likely to help
Patients with other types of dementia or those with advanced stages of dementia may not benefit from this research.
What this research studies
This research focuses on evaluating the effectiveness of neflamapimod, a specific inhibitor targeting a key enzyme involved in neurodegeneration, in patients with mild-to-moderate dementia with Lewy bodies (DLB). The study aims to assess how this oral medication can improve cognitive and motor symptoms associated with DLB, which currently has no approved treatments. Participants will be monitored for changes in their symptoms and overall quality of life throughout the trial period. The research is designed to provide insights into the potential of neflamapimod to address the underlying causes of DLB.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly alleviates symptoms and improves the quality of life for patients with dementia with Lewy bodies.
How similar studies have gone: Previous studies have shown promise with similar approaches targeting neurodegenerative mechanisms, suggesting potential for success in this research.
Where this research is happening
-
Eip Pharma, INC.
Boston, United States Active
Researchers
- Principal investigator: Alam, John — Eip Pharma, INC.
- Study coordinator: Alam, John
Related research
Other NIH-funded projects on the same topics.
-
Understanding how heparan sulfate affects alpha-synuclein in Lewy body dementia
A small study in people who have dementia with Lewy bodies looks at how a brain sugar (heparan sulfate) helps a harmful protein (alpha-synuclein) spread, with the hope of slowing disease progression.
-
Alpha-synuclein seed test in blood or urine for Parkinson’s and Lewy body diseases
A new blood or urine test using seed amplification to help diagnose Parkinson’s disease, dementia with Lewy bodies, and related conditions earlier and more clearly.
-
Dementia with Lewy Bodies Consortium
A national research effort to better understand and diagnose Lewy body dementia by studying biomarkers and patient data over time.
-
Rat model of dementia with Lewy bodies may help us study memory and movement problems
A scientist team is creating and validating a rat model that mirrors Dementia with Lewy Bodies to better understand how it develops and to test potential treatments.
-
Proof of Concept Study on Clinical Trial Outcomes and Biomarkers in Early Lewy Body Dementia
A small, early-stage study is testing whether new biomarkers and trial outcomes can better measure symptoms and treatment effects for people with Lewy body dementia.
-
Amyloid-clearing therapy for dementia with Lewy bodies plus Alzheimer's disease
A study tests an amyloid-clearing antibody in people who have both Dementia with Lewy bodies and Alzheimer's disease to see if it can safely help with their symptoms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.